ChromaDex Co. (NASDAQ:CDXC – Get Free Report)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.99 and traded as high as $3.47. ChromaDex shares last traded at $3.45, with a volume of 199,600 shares trading hands.
Analyst Upgrades and Downgrades
CDXC has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of ChromaDex in a report on Friday, August 9th. Roth Mkm reaffirmed a “buy” rating and issued a $6.00 price target on shares of ChromaDex in a research note on Wednesday, June 12th.
Read Our Latest Stock Analysis on CDXC
ChromaDex Price Performance
Insider Buying and Selling at ChromaDex
In related news, Director Kristin Patrick sold 23,000 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 9.64% of the company’s stock.
Institutional Investors Weigh In On ChromaDex
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Miracle Mile Advisors LLC acquired a new stake in ChromaDex during the 2nd quarter worth $27,000. The Manufacturers Life Insurance Company purchased a new position in shares of ChromaDex during the second quarter worth about $31,000. Merriman Wealth Management LLC acquired a new position in ChromaDex in the 2nd quarter valued at about $32,000. Lazard Asset Management LLC purchased a new stake in ChromaDex during the 1st quarter valued at approximately $43,000. Finally, SG Americas Securities LLC acquired a new stake in ChromaDex during the 1st quarter worth approximately $54,000. 15.41% of the stock is currently owned by institutional investors and hedge funds.
About ChromaDex
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Read More
- Five stocks we like better than ChromaDex
- What is a Special Dividend?
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- Market Cap Calculator: How to Calculate Market Cap
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.